RemeGen
09995.HK, 688331.SHYantai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileOverview
A leading Chinese biotech developing and commercializing innovative biologics and ADCs for autoimmune diseases, oncology, and ophthalmology.
OncologyImmunologyOphthalmology
Technology Platform
Proprietary platforms for antibody-drug conjugate (ADC) development and dual-target fusion protein technology (e.g., targeting BLyS/APRIL or VEGF/FGF).
Opportunities
Significant growth opportunities exist from label expansions of Telitacicept into multiple autoimmune indications and of Disitamab Vedotin into new cancer types and treatment settings, as well as geographic expansion through partnerships like the Santen deal for RC28.
Risk Factors
Key risks include intense competition in core therapeutic areas (HER2 ADCs, SLE therapies), potential pricing pressure in China, and execution risks associated with commercial scaling and the clinical development of later-stage pipeline candidates.
Competitive Landscape
In oncology, Disitamab Vedotin competes with other HER2 ADCs like Enhertu (AstraZeneca/Daiichi Sankyo) in a crowded field, differentiating itself with a proprietary linker-payload and strong China data. In immunology, Telitacicept's dual BLyS/APRIL inhibition offers a mechanistic distinction versus single-target agents like belimumab.